Cargando…

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofheinz, R.-D., Ronellenfitsch, U., Kubicka, S., Falcone, A., Burkholder, I., Hacker, U. T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021498/ https://www.ncbi.nlm.nih.gov/pubmed/27656206 http://dx.doi.org/10.1155/2016/9189483

Ejemplares similares

Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer
por: Moisuc, Diana Cornelia, et al.
Publicado: (2022)

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
por: Fuloria, Jyotsna
Publicado: (2012)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
por: Ge, Pu, et al.
Publicado: (2023)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009)

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
por: Jones, Robin L., et al.
Publicado: (2017)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
por: Cremolini, Chiara, et al.
Publicado: (2017)

Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer
por: Satake, Hironaga, et al.
Publicado: (2022)

Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial
por: Sandra-Petrescu, Flavius, et al.
Publicado: (2018)

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set
por: Grothey, Axel, et al.
Publicado: (2018)

Suppression of Autoimmune Retinal Inflammation by an Antiangiogenic Drug
por: Yoshimura, Takeru, et al.
Publicado: (2013)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
por: Ebos, John ML, et al.
Publicado: (2014)

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis
por: Yi, SuYi, et al.
Publicado: (2017)

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
por: Xiao, Bingkun, et al.
Publicado: (2018)

Perivascular cell‐derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs
por: Huang, Maohua, et al.
Publicado: (2021)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database
por: Shinozaki, Eiji, et al.
Publicado: (2021)

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
por: Rodriguez-Pascual, Jesus, et al.
Publicado: (2017)

Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases
por: Qu, Hui, et al.
Publicado: (2023)

Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
por: Jonker, D J, et al.
Publicado: (2000)

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
por: Karthaus, Meinolf, et al.
Publicado: (2016)

Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results
por: Hofheinz, Ralf, et al.
Publicado: (2014)

Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs
por: Coschignano, Maria Antonietta, et al.
Publicado: (2021)

Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
por: Sun, Qi, et al.
Publicado: (2022)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Antiangiogenic Activity of Flavonoids: A Systematic Review and Meta-Analysis
por: Khater, Mai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4q57thuc7qrimjj167a4oupdd6